evaluation of ultrasensitive crP and microalbuminuria as cardiovascular risk markers in type 2 diabetic moroccan patients.

##plugins.themes.academic_pro.article.sidebar##

Published May 3, 2018
Download
pdf
Vol. 95 No. 11 (2017): Issue Nov 2017

##plugins.themes.academic_pro.article.main##

Fatima El Boukhrissi
Imane Benbella
Hassan Ouleghzal
Soumia Safi
Youssef Bamou
Lhousain Balouch

Abstract

Introduction: Type 2 diabetes is a chronic disease whose prevalence is increasing exponentially. This condition is a risk factor for cardiovascular
disease, the leading cause of death among diabetics.
Objective: To study the correlation between hs CRP, microalbuminuria, diabetes monitoring parameters and the presence of vascular
complications in a group of non-insulin dependent diabetic patients followed in endocrinology department of the Moulay Ismail Military Hospital in
Meknes.
Methods: The study involved 250 patients with type 2 diabetes and 120 control subjects. Patients were subduvised on 2 groups: group I consisting
of patients without diabetes vascular complications. Group II involved patients with at least one vascular complication. The parameters measured
were age, sex, BMI, duration of diabetes and the presence of vascular complications. The studied biological parameters were hs CRP,
microalbuminuria, HbA1c and lipid profile.
Results: Diabetic patients with complications had significantly higher levels of hs CRP and microalbuminuria compared with diabetic patients
without complications and with controls (8.37 vs 5.94 vs 2.63; p <0.001 vs 62.10 34 56 vs 5.67; p <0.0001). The rate of hs CRP were significantly
correlated with HA1c, total cholesterol, the LDL-C, index atherogenicity microalbuminuria and duration of diabetes for the two patient groups. A
significant correlation between hs CRP and age was only found in Group I.
Conclusion: CRP appears to be interested in the detection of vascular complications in diabetic type2.

Keywords:

Type 2 diabetes ; protein C-réactive ; microalbuminuria ; cardiovascular complication ; chronic inflammation.

##plugins.themes.academic_pro.article.details##

References

  1. Centre des médias :Organisation mondiale de la santé.Maladies non transmissibles. Aide-mémoireN°355. Mars 2013.[cited 2016 Sep14]Available from :http://www.who.int/media centre/factsheets/fs355/fr.
  2. Puglisi MJ, Fernandez ML. Modulation of C-reactive protein, tumor necrosis-alpha and adiponectin by diet, exercise and weight loss. J Nutr 2008;138(12):2293-6.doi:10.3945/jn.108.097188.doi: 10.3945/jn.108.097188.
  3. Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Applied Physiol 2005;98(4):1154-62.
  4. Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of Creactive protein on human endothelial cells. Circulation 2000;102(18):2165-8.
  5. Pasceri V, Chang JS, Willerson JT, Yeh ET. Modulation of Creactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs.Circulation 2001;103(21):2531-4.
  6. Pannacciulli N, Cantatore FP, Minenna A, Bellacicco M, Giorgino R, De Pergola G. C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int J ObesRelatMetabDisord. 2001 Oct;25(10):1416-20.
  7. Coulon J, Willems D, Dorchy H. augmentation de la concentration plasmatique de la protéine C-réactive dans le diabète de l'enfant et de l'adulte jeune. Presse Med 2005;34:89-93.
  8. El Oudi M, Aouni Z, Ouertani H et al. CRP et microalbuminurie : nouveaux marqueurs du risque cardiovasculaire chez les diabétiques de type 2.Ann CardiolAngeiol (Paris) 2011;60:207-210.
  9. Hu FB, Meigs JB, Li TY, Rifai N, Manson JE.Inflammatory markers and risk of developing type2diabetesinwomen.Diabetes2004;53:693-700.
  10. Alexandraki K, Piperi C, Kalofoutis C, Singh J, Alaveras A, Kalofoutis A. Inflammatory process in type 2 diabetes: the role of cytokines. Ann NY AcadSci 2006;1084:89-117.
  11. Torzewszki M, Rist C, Mortensen RFet al. C-reactive proteinin the arterial intima: role of C-reactive proteinreceptor-dependent monocyte recruitement in atherogenesis.ArteriosclerThrombVascBiol 2000;20:2094-9.
  12. Verma S, Wang CH, Lonn E et al. Cross-sectional evaluationof brachial artery flow-mediated vasodilatation andC-reactive protein in healthy individuals. Eur Heart J2004; 25(19):1754-60.
  13. Cushman M, Arnold M A, Bruce M et al. C-Reactive Protein and the 10-Year Incidence of Coronary Heart Disease in Older Men and Women The Cardiovascular Health Study. Circulation. 2005;112:25-31.
  14. Nakamura M, Onoda T, Itai K et al. Association betweenserumC-reactiveproteinlevelsandmicroalbuminurie:a population basedcross-sectionalstudyinnorthernIwate,Japan.Intern Med 2004;43:919-25.
  15. Kanwar YS, Wada J, Sun L, et al. Diabetic nephropathy: mechanisms of renal disease progression.ExpBiol Med (Maywood) 2008;233(1):4-11.
  16. Gerstein HC, Mann JF, Yi Qet al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-6.
  17. Stehouwer CD, Nauta JJ, Zeldenrust GC et al. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992;340:319- 23.
  18. Bilous R. Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?.Diabet Med 2008;25(Suppl 2):25-9.